Literature DB >> 31203233

Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D.

Arpita Basu1, Ionut Bebu2, Alicia J Jenkins3, Julie A Stoner4, Ying Zhang4, Richard L Klein5,6, Maria F Lopes-Virella5,6, W Timothy Garvey7, Matthew J Budoff8, Petar Alaupovic9, Timothy J Lyons10.   

Abstract

APOB, APOC3, and APOE and apolipoprotein-defined lipoprotein subclasses (ADLSs; based on qualitative apolipoprotein complement) have been associated with dyslipidemia and CVD. Our main objective was to define associations of serum apolipoproteins and ADLSs with "any CVD" and "major atherosclerotic cardiovascular events" (MACEs) in a prospective study of T1D. Serum apolipoproteins and ADLSs (14 biomarkers in total) were measured in sera (obtained between 1997 and 2000) from a subset (n = 465) of the Epidemiology of Diabetes Interventions and Complications cohort. Prospective associations of "any CVD" (myocardial infarction, stroke, confirmed angina, silent myocardial infarction, revascularization, or congestive heart failure) and MACEs (fatal or nonfatal myocardial infarction or stroke), over 5,943 and 6,180 patient-years follow-up, respectively, were investigated using Cox proportional hazards models that were unadjusted and adjusted for risk factors. During 15 years of follow-up, 50 "any CVD" events and 24 MACEs occurred. Nominally significant positive univariate associations with "any CVD" were APOB, APOC3 and its subfractions [heparin precipitate, heparin-soluble (HS)], and ADLS-defined Lp-B. In adjusted analyses, APOC3-HS remained nominally significant. Nominally significant positive univariate associations with MACEs were APOC3 and its subfractions and Lp-B:C; those with total APOC3 and APOC3-HS persisted in adjusted analyses. However, these associations did not reach significance after adjusting for multiple testing. There were no significant associations of APOA1, APOA2, APOE, or other ADLSs with either "any CVD" or MACEs. These hypothesis-generating data suggest that total serum APOC3 and APOC3 in HDL are potentially important predictive biomarkers for any CVD and MACEs in adults with T1D.

Entities:  

Keywords:  apolipoprotein C3; major adverse cardiac event; type 1 diabetes

Mesh:

Substances:

Year:  2019        PMID: 31203233      PMCID: PMC6672041          DOI: 10.1194/jlr.P090647

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  48 in total

1.  Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes.

Authors:  N Gervaise; M A Garrigue; G Lasfargues; P Lecomte
Journal:  Diabetologia       Date:  2000-06       Impact factor: 10.122

2.  High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database.

Authors:  Sabita S Soedamah-Muthu; John H Fuller; Henrietta E Mulnier; Veena S Raleigh; Ross A Lawrenson; Helen M Colhoun
Journal:  Diabetes Care       Date:  2006-04       Impact factor: 19.112

3.  Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.

Authors:  T J Lyons; A J Jenkins; D Zheng; R L Klein; J D Otvos; Y Yu; D T Lackland; D McGee; M B McHenry; M Lopes-Virella; W T Garvey
Journal:  Diabet Med       Date:  2006-09       Impact factor: 4.359

4.  ApoC-III bound to apoB-containing lipoproteins increase with insulin resistance in Cherokee Indian youth.

Authors:  Piers R Blackett; Kathleen S Blevins; Elaine Quintana; Martha Stoddart; Wenyu Wang; Petar Alaupovic; Elisa T Lee
Journal:  Metabolism       Date:  2005-02       Impact factor: 8.694

5.  Identification of apoB-containing lipoprotein families in NIDDM.

Authors:  P Alaupovic; J M Bard; M Tavella; D Shafer
Journal:  Diabetes       Date:  1992-10       Impact factor: 9.461

6.  Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes.

Authors:  S P Laing; A J Swerdlow; S D Slater; A C Burden; A Morris; N R Waugh; W Gatling; P J Bingley; C C Patterson
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

7.  Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.

Authors:  David M Nathan; John Lachin; Patricia Cleary; Trevor Orchard; David J Brillon; Jye-Yu Backlund; Daniel H O'Leary; Saul Genuth
Journal:  N Engl J Med       Date:  2003-06-05       Impact factor: 91.245

8.  Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men.

Authors:  Karin Wallenfeldt; Lena Bokemark; John Wikstrand; Johannes Hulthe; Björn Fagerberg
Journal:  Stroke       Date:  2004-09-02       Impact factor: 7.914

9.  Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group.

Authors: 
Journal:  Diabetes Care       Date:  1992-07       Impact factor: 19.112

Review 10.  The concept of apolipoprotein-defined lipoprotein families and its clinical significance.

Authors:  Petar Alaupovic
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

View more
  11 in total

Review 1.  Intracellular and Intercellular Aspects of Macrophage Immunometabolism in Atherosclerosis.

Authors:  Ira Tabas; Karin E Bornfeldt
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

2.  Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.

Authors:  Jenny E Kanter; Baohai Shao; Farah Kramer; Shelley Barnhart; Masami Shimizu-Albergine; Tomas Vaisar; Mark J Graham; Rosanne M Crooke; Clarence R Manuel; Rebecca A Haeusler; Daniel Mar; Karol Bomsztyk; John E Hokanson; Gregory L Kinney; Janet K Snell-Bergeon; Jay W Heinecke; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2019-07-11       Impact factor: 14.808

Review 3.  Emerging Targets for Cardiovascular Disease Prevention in Diabetes.

Authors:  Nathan O Stitziel; Jenny E Kanter; Karin E Bornfeldt
Journal:  Trends Mol Med       Date:  2020-05-15       Impact factor: 11.951

4.  Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.

Authors:  Ye-Xuan Cao; Hui-Wen Zhang; Jing-Lu Jin; Hui-Hui Liu; Yan Zhang; Rui-Xia Xu; Ying Gao; Yuan-Lin Guo; Cheng-Gang Zhu; Qi Hua; Yan-Fang Li; Raul D Santos; Na-Qiong Wu; Jian-Jun Li
Journal:  J Lipid Res       Date:  2020-07-08       Impact factor: 5.922

5.  CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins.

Authors:  Masami Shimizu-Albergine; Debapriya Basu; Jenny E Kanter; Farah Kramer; Vishal Kothari; Shelley Barnhart; Carissa Thornock; Adam E Mullick; Noemie Clouet-Foraison; Tomas Vaisar; Jay W Heinecke; Robert A Hegele; Ira J Goldberg; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

Review 6.  Cardiovascular Disease in Adults with Type 1 Diabetes: Looking Beyond Glycemic Control.

Authors:  Rachel G Miller; Tina Costacou
Journal:  Curr Cardiol Rep       Date:  2022-08-10       Impact factor: 3.955

Review 7.  The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease.

Authors:  Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-05-26       Impact factor: 10.514

Review 8.  Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.

Authors:  Alan Chait; Henry N Ginsberg; Tomas Vaisar; Jay W Heinecke; Ira J Goldberg; Karin E Bornfeldt
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

9.  Apolipoprotein C-III predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria.

Authors:  Fanny Jansson Sigfrids; Lars Stechemesser; Emma H Dahlström; Carol M Forsblom; Valma Harjutsalo; Raimund Weitgasser; Marja-Riitta Taskinen; Per-Henrik Groop
Journal:  J Intern Med       Date:  2021-11-24       Impact factor: 13.068

Review 10.  Cardiovascular disease in diabetes, beyond glucose.

Authors:  Robert H Eckel; Karin E Bornfeldt; Ira J Goldberg
Journal:  Cell Metab       Date:  2021-07-21       Impact factor: 31.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.